Determination of Zinc, Copper, Cadmium and Lead in Serum of Patients with Acute Leukemia

Mahmoud. A. Ghandour1*, Ahmad F. Thabet2 and Rafallah M.A. Mohamed3

1 Chemistry Department, Faculty of Science, Assiut University, Assiut-71516 - Egypt
2 Department of internal medicine, Faculty of Medicine Assiut University, Assiut-71516- Egypt
3Department of Chemistry, Faculty of Science, Misurata University, Misurata - Libya

Abstract: The relations between malignant hematological diseases and trace heavy metals in blood have not been understood clearly. Alterations in serum Zn and Cu levels may frequently occur in many neoplastic diseases, including leukemia. Therefore, it is necessary from an analytical point of view to develop sensitive and economical methods for the determination of trace amount of heavy metals and the relationship between changes in concentrations of these metals and the development of hematological malignancies. Differential Pulse Stripping Voltammetry (DPAdSV) is relatively inexpensive and is one of the most sensitive and selective techniques in the determination of trace amounts of metals. The levels of heavy metals such as Zn, Cu, Pb and Cd were determined in the serum of 20 patients with acute leukemia before initial chemotherapeutic treatment and compared to 15 apparently healthy control group using two different analytical techniques; (DPAdSV) and inductively coupled plasma optical emission spectrometry (ICP-OES). The selection criteria for the patients and controls were the lack of recent blood transfusion history and taking any medication with mineral supplement. The Serum levels of Cu, Zn and Cd were significantly lower with acute leukemia than controls (p=0.003, p=0.035, p=0.014, respectively), while Pb was insignificantly elevated (p=0.381). Conclusion: In this study, we found the levels of Cu, Zn and Cd to be lowered and of lead to be elevated in patients with acute leukemia. Further studies are needed to clarify the role of these elements in pathogenesis of acute leukemia. And also a comparative study was carried out between the results using DPAdSV and ICP-OES techniques, which are in very good agreement.

Keywords: Acute Leukemia, Serum, Stripping Voltammetry, Zinc

1. Introduction

Acute leukemia is a clonal malignant disorder affecting all age groups. It is characterized by the accumulation of immature blast cells in the bone marrow. This results in bone marrow failure, reflected by peripheral blood cytopenias and circulating blast cells. In most cases the etiology is not obvious, but internal and external factors associated with damage to DNA can predispose to acute leukemia [1]. Blood is the transport medium for the nutrients and trace metals to and from the tissues and, therefore, provides rapid and reliable information about the trace metal metabolism in human body [2,3]. Several studies have been reported in the recent years regarding the trace metal evaluation in the body liquids but because of natural significance and ease of sampling, blood is the most commonly used specimen. Consequently, whole blood, serum and plasma have been used in biological research for the determination of trace metal status of individuals and groups [4-6]. Zinc plays a key role in cell membrane integrity and is a component of more than 300 different enzymes for the functioning of the cellular activity and the metabolism of proteins, lipids and carbohydrates [7]. Zinc deficiency can produce growth retardation, anorexia, delayed sexual maturation, anemia, mental retardation, impaired visual and immunological function, etc., while excessive Zn intake might interfere with the Cu absorption, impair the lymphocyte and neutrophil function or reduce the serum concentration of the high density lipoprotein cholesterol [8]. Copper is an economically important element that is found in only trace quantities in the Earth's crust. For both plants and animals it is required as a trace nutrient, but excessive amounts are toxic [9]. High amounts of copper in the human body can cause stomach and intestinal distress such as nausea, vomiting and diarrhea. Copper and zinc have been associated with normal lymphocyte maturation and regulation of immune function. Low levels of these minerals have been demonstrated in a variety of dysfunctions of the immune system [10]. Serum concentrations of copper and zinc are modified in some cancers; serum copper concentrations may be increased in some leukemias [11], and lymphomas [12], whereas variations of zinc concentrations have been demonstrated in leukemia. The levels of Cd and Pb in the human body have a great toxicological significance being responsible for a number of health impairments. In particular, Cadmium is known as a highly toxic metal that represents a major hazard to the environment and humans. The extremely long biologic half-life (30-35 years) makes it a cumulative toxicant, with liver and kidney as the main organs of accumulation [13]; therefore, long-term past exposure could still result in direct toxic effects [14]. The toxicity
of this metal contributes to a large variety of health conditions, including the most important diseases such as heart disease, cancer, and diabetes [15-19].

Lead is known to be a toxic metal that accumulates in the human body throughout the lifetime. Its cumulative poisoning effects are serious hematological damage, brain damage, anemia, and kidney malfunctioning [20]. Imbalances in the optimum levels of these trace elements may adversely affect biological processes and are associated with many fatal diseases, such as cancer. There are several reports on serum trace element levels in malignant diseases including leukemia and lymphomas [21]. But, there are contradictory data between the previous studies, done related to the trace elements state in acute leukemia [22].

II. Experimental

Study Subjects

This study included twenty patients were newly diagnosed as acute leukemia (9 females and 11 males) aged between 20 and 50 years. Diagnosis of acute leukemia based on symptoms, physical finding as well as complete blood picture with total and differential leucocytic count, bone marrow aspirate and immunophenotyping when needed. All the patients were enrolled in the study before receiving any chemotherapeutic agents. The selection criteria for the patients and controls were the lack of recent blood transfusion history and taking any medication with mineral supplement. The patients were recruited from clinical hematology unit, Internal Medicine department, Assiut University Hospital. The control group consisted of fifteen healthy subjects (6 females and 9 males) aged between 20 and 45 years were chosen for our study and approved by the Ethic Committee.

Sample collection and processing

Blood samples (5 ml) of patients were collected by venous puncture. Blood samples of control were collected from the same areas of patients. The puncture site was cleaned to remove any expected contamination before sampling. Separate and disposable sterilized plastic syringes were used for blood collection. The blood sample was left standing for 1h to coagulate; serum was separated at 3500 rpm centrifugation for 10 min, transferred to 5 ml polystyrene tube, and stored at -5 °C until analysis.

Reagents and solutions

All reagents are of analytical grade. Solution of each Zn(II), Cu(II), Pb(II) and Cd(II) were prepared respectively by dissolving the required amounts of Zn(NO$_3$)$_2$.3H$_2$O, Cu(NO$_3$)$_2$.2H$_2$O, Pb(NO$_3$)$_2$ and Cd(NO$_3$)$_2$.4H$_2$O in bidistilled water.

Instrumentation

All glassware was soaked in 10% (v/v) HNO$_3$ for 24 h and rinsed three times with distilled water and then in redistilled water before use:

Anodic differential pulse stripping voltammograms were recorded by polarographic Analyzer stripping voltammetric Model 264 A (EG&G, Princeton Applied Research; Princeton, NJ, USA), coupled with a PAR 303 A Static Mercury Drop Electrode (SMDE; drop size: medium, area of the drop: 0.014 cm$^2$). The polarographic cell bottom (PAR Model K 0060) was fitted with Ag/AgCl saturated KCl, reference electrode, and platinum wire used as a counter electrode. A PAR 305 stirrer was connected to the 303 SMDE. A PAR Model RE 0089 X-Y recorder was used for recording the voltammograms. Before measurements the sample solution was deaerated by bubbling for 16 minutes with nitrogen. During measurements, an inert atmosphere over the solution was maintained by flushing with nitrogen. During the deposition step, the solution was stirred automatically, followed by a quiescent period of 15 sec before scanning.

All the determinations were carried out by inductively coupled plasma optical emission spectrometry (ICP-OES). Thermo Fisher Scientific Announces Enhanced iCAP 6200 Optical Emission Spectrometer was used with the following operating conditions: Nebulizer Gas flow rates: 0.6 l/min; Auxiliary Gas Flow: 0.5 l/min; Coolant Gas Flow: 12 l/min; Nebulizer Argon Flow: 0.6 l/min; Pumb Speed: 45 rpm; RF Forward Power: 1150 Prior to analysis.

- pH was measured with Hanna microprocessor pH model 211.

Sample digestion

One milliliter serum sample was wet digested in covered glass beaker containing a 10mL (1:1) HNO$_3$ / HClO$_4$ acid mixture. The digest was transferred in to a 25 mL pre-cleaned measuring flask, diluted to the mark with double distilled water, and stored for analysis. Blank solution was treated and prepared in the same way as the samples. Each sample and each blank were prepared in triplicate.

Corresponding author. E-mail address: ghandour0100@yahoo.com
Analytical procedure: the following parameters were used to perform Differential Pulse Anodic Stripping Voltammetry (DPASV). Scan rate 10 mVs⁻¹ with duration for 1 sec and pulse amplitude (AE) 25 mV. For determination of Zn(II), Cu(II), Pb(II) and Cd(II) in blood serum in patients with acute leukemia and control in the same cell.

5 mL of each sample solution and 1 mL of 0.1 M HNO₃ solution as supporting electrolyte were transferred into the electrolysis cell and completed to 10 mL using bidistilled water (pH ~ 2). The solution was deaerated by passing pure nitrogen for 16 min. The deposition potential were controlled at -1.2, -0.25, -0.6 and -0.75 V vs. Ag/AgCl sat'd KCl respectively and applied to a fresh mercury drop while the solution was stirred. After the deposition step and further 15 sec. (equilibrium time) the voltammogram was recorded.

Different concentration from the standard metal ion (individually) were added to the cell using an automatic pipette, while keeping the deposition time constant. The solution was stirred and purged with nitrogen for 30 sec. after each spike. The concentration of each Zn(II), Cu(II), Pb(II) and Cd(II) in the electrolytic cell was calculated in the sample solutions by using standard addition method. Then the concentration in μg/ml of each blood serum in patients with acute leukemia and control were calculated and compared.

Statistical Analysis:
Statistical analyses were carried out using the SPSS statistical software package (SPSS for Windows version 13.0, SPSS Inc., Chicago, Illinois, USA). All results are expressed as mean and standard deviation (mean ± SD). A “p” value <0.05 was considered statistically significant.

III. Results And Discussion
This study included twenty patients were newly diagnosed as acute leukemia (AML: 15; ALL: 5), 9 females and 11 males aged between 20 and 50 years. Their clinical and laboratory data shown in table (1).

Optimal conditions for the determination of Zn(II), Cu(II), Pb(II) and Cd(II) by DPASV technique
Preliminary experiments have been carried out to investigate the effect of various operational parameters on the differential pulse anodic stripping response. The anodic peak currents were studied with respect to the supporting electrolyte compositions, pH, deposition potential, scan rate and deposition time to optimize the conditions for analytical utility to obtain the highest peak signal for metal ions Zn(II), Cu(II), Pb(II) and Cd(II) in serum solution samples. It was noticed that, 0.01 M nitric acid solution (pH ~ 2) gave promising results for the determination of Zn(II), Cu(II), Pb(II) and Cd(II) ions.

The effect of deposition potential of each metal ion was studied and it was observed that the highest and best shape peaks for Zn(II), Cu(II), Pb(II) and Cd(II) were at deposition potentials -1.2, -0.25, -0.6 and -0.75 V vs. Ag/AgCl sat'd KCl, respectively. The effective scan rate which gives a suitable peak height of each metal was 10 mV/sec.

The effect of deposition time on the oxidation peak signals of these metal ions was examined. Fig. 1 show the differential pulse anodic stripping voltammograms of Zn(II) in blood serum of patients with acute leukemia in acid solution at different deposition times. The optimal deposition times were selected for these metal ions of all sample solutions in a manner that linear relation must be established between deposition times and current signals.

Concentration of Zn(II), Cu(II), Pb(II) and Cd(II) in blood serum of patients with acute leukemia and control as determined by stripping voltammetry technique and inductively coupled plasma optical emission spectrometry.

The results of Zn(II), Cu(II), Pb(II) and Cd(II) concentrations in blood serum of control and patients with acute leukemia as determined by DPASV and ICP-OES are presented in Table 2. The mean Zn(II), Cu(II), Pb(II) and Cd(II) concentrations in blood serum of patients with acute leukemia are 0.5606, 0.8180, 0.2336 and 0.0102 μg/ml, respectively, while in control are 0.753, 0.4070, 0.2988 and 0.0297 μg/ml, respectively. The results of the studied Zn(II), Cu(II), Pb(II) and Cd(II) in blood serum of patients with acute leukemia and control are discussed as follows.

Determination of Zn(II)
Fig. 2 represents the differential pulse anodic stripping voltammograms of zinc in blood serum sample solution of patients with acute leukemia in absence and in presence of added standard zinc solution in nitric acid solution of pH ~ 2. On plotting of peak current against concentrations for twenty blood serum sample solutions of patients with acute leukemia and control in the same supporting electrolyte at the same conditions, straight lines are obtained. From the interceptions of these lines with the concentration axis at zero current signals, one can calculate the concentration of Zn(II) in each sample.

Our result shows that the mean serum zinc level was significantly lower in leukemia patients (0.5606 μg/ml) than in the healthy control (0.9753 μg/ml; Table 2; Fig. 6), with p value =0.035 (Table 3).
Our results were in agreement with the majority of studies, which mostly showed lower level of zinc in leukemic patients than control, as in Zuo et al., 2006 [22] study who found that the mean Zn level of 0.642 μg/ml in the blood serum of patients with acute leukemia was lower than that detected in the blood serum of controls 0.984 μg/ml, and also with Demir et al., 2011 [23] study who reported that, the mean concentration of serum zinc (0.494 μg/ml) was lower in patients with leukemia than in controls (1.108 μg/ml).

Our results are in agreement with Schwartz, 1975 study [24] who reported that there are some data suggesting an association between the deficiency of Zn and the development of malignant disorders, and with Brown et al., 1980 study[25], that experimental results support towards slightly decreased zinc concentrations in malignant diseases. Also our results are in agreement with Demir et al., 2011[23] and Sahin et al., 2000[26] in their study that showed decreases in Zn levels in patients with acute leukemia when compared with controls.

**Determination of Cu(II)**

Fig. 3 shows the differential pulse anodic stripping voltammograms of Cu(II) in blood serum sample of patients with acute leukemia spiked with different concentration of copper ions in nitric acid solution of pH ~2. On plotting of $i_p$ vs. Cu(II) concentrations for all blood serum samples in the same supporting electrolyte at the same conditions, straight lines are obtained (standard addition method). From the interceptions of these lines with the concentration axis at zero current signals, one can calculate the concentration of Cu(II) in each sample. The mean serum copper level in patients with acute leukemia (0.818 μg/ml) was significantly higher than that found in control (0.407 μg/ml) as shown in Table 2; Fig. 6, with P value=0.003 (Table 3). Our result is in agreement with that of Zuo et al., 2006 [22], Demir et al., 2011 [23] and Akkuş et al., 1998 [27] in which the serum Cu level in patient with leukemia was significantly higher than that in controls. They found that the serum copper levels in patients with leukemia were 1.291, 1.226 and 5.251 μg/ml and in controls were 0.867, 1.047 and 1.150 μg/ml respectively.

Our results are in agreement with Tessmer et al., 1972; [21] Carpentieri et al., 1986 [28], Osman et al., 1983;[29] and Akkus et al., 1998 [27] studies in leukemic patients in which serum Cu levels have been found to be higher than those of controls. Also our results in agreement with Tessmer et al., 1972 [21] and Ilicin, 1971 [30] who suggested that serum copper would be a useful indicator for the extent of leukemia and malignant lymphoma, and might be a predictor for chemotherapy response and they added that remission is usually associated with the return of Cu levels to normal ranges.

**Determination of Pb(II)**

The differential pulse anodic stripping voltammograms of lead in blood serum sample solution of patients with acute leukemia in absence and in presence of standard lead ions is shown in Fig. 4. The plots of peak current against concentration, a straight lines are obtained. From the interception of these lines with the concentration axis at zero current signal gives the concentration of Pb(II) in the voltammetric cell for each sample. The mean serum lead level was lower in leukemic patients (0.2336 μg/ml) than in the control (0.2988 μg/ml) but without significant value as shown in Table 2; Fig. 6, with P value= 0.381 (Table 3). Our results not in agreement with Demir et al., 2011 study [24] who found that levels of Pb were high in serum of acute leukemia compared to the control group but they add that literature data about Pb are more controversial and that no study evaluating Pb metal levels in acute leukemia in the literature. Further studies are necessary to interpret this finding better and to clarify the role of lead in the pathogenesis of leukemia.

**Determination of Cd(II)**

The differential pulse anodic stripping voltammograms of cadmium in blood serum sample solution of leukemia patient in absence and in presence of standard zinc ions is shown in Fig. 5. On plotting of peak current against concentrations for twenty blood serum sample solutions of leukemia patient and fifteen healthy control in the same supporting electrolyte at the same conditions, straight lines are obtained (standard addition method). From the interceptions of these lines with the concentration axis at zero current signals, one can calculate the concentration of Cd(II) in each sample.

The result shows that the mean serum cadmium level was significantly lower in leukemia patients (0.0102 μg/ml) than in the healthy control (0.0297 μg/ml; Table 2; Fig. 6), with P value=0.014 (Table 3). Our findings differ from that reported by Demir et al., 2011 study [24] who reported that Cd levels were higher in patients with leukemia compared to healthy group but he added that most studies have been made more in solid organ cancers and cadmium and they did not find a study that examined the association between acute leukemia and cadmium. More comprehensive studies are needed to clarify the pathogenesis of the acute leukemia and its relation to cadmium.
Determination Of Zinc, Copper, Cadmium And Lead In Serum Of Patients

Comparison of the analytical methods

A comparative study was carried out between the results of Zn(II), Cu(II), Pb(II) and Cd(II) in healthy blood serums obtained using differential pulse adsorptive stripping voltammetry (DPAdSV) and inductively coupled plasma optical emission spectrometry (ICP-OES). A comparison of the results is shown in (Table 2). It was proved that the results obtained using stripping voltammetry for Zn(II), Cu(II), Pb(II) and Cd(II) (0.969, 0.407, 0.2988 and 0.0297 μg/ml, respectively) nearly in agreement with those obtained using inductively coupled plasma optical emission spectrometry of the same elements (1.080,0.519, 0.349 and 0.01297 μg/ml, respectively) for healthy control. Generally, the data obtained by inductively coupled plasma optical emission spectrometry are in close agreement with those obtained by stripping voltammetry for some metals and slight differences for the others. However, the slight differences that may be found sometimes between both techniques are mainly due to the manipulation of the analyst and metal interferences in cases of inductively coupled plasma optical emission spectrometry while the standard addition method is used to perform the stripping voltammetry technique. The standard addition method is more accurate than the calibration curves, since additions of the standard analyst to the sample give precise results and minimize or even avoid the interferences usually inherent with the matrix analysis [31].

IV. Conclusion

In this study we found the levels of copper, Zinc and cadmium to be lower and of lead to be elevated in patients with acute leukemia. Further studies are needed to clarify the role of these elements in pathogenesis of acute leukemia. And also a comparative study was carried out between the results using DPAdSV and ICP-OES techniques, which are in very good agreement.

References


www.iosrjournals.org
Determination Of Zinc, Copper, Cadmium And Lead In Serum Of Patients


I. Akkus, M. Gürbilek, Ü. Çalışkan, B. Kaptanoğlu and A. Üner, Blood and Fingernail Copper (Cu) and Magnesium (Mg) Levels of Children With Acute Lymphoblastic Leukemia, Tr. J. of Medical Sciences, 28, 1998, 155-156.


Table (1): Clinical (symptoms and signs) and laboratory data of studied patients

<table>
<thead>
<tr>
<th>Symptoms and signs</th>
<th>Number and percentage of total (20 patients)</th>
<th>Parameters</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td></td>
<td>WBC Count (×10^9/L)</td>
<td>47.3 ± 2.37</td>
</tr>
<tr>
<td></td>
<td>Intermediate grade</td>
<td>ANC (×10^9/L)</td>
<td>1.4 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>High grade</td>
<td>Hemoglobin level (g/dl)</td>
<td>7.56 ± 0.283</td>
</tr>
<tr>
<td>Pallor</td>
<td>18 (90%)</td>
<td>AST (IU/L)</td>
<td>36.7±0.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALT (IU/L)</td>
<td>39.1±0.97</td>
</tr>
<tr>
<td>Jaundice</td>
<td>2 (10%)</td>
<td>Platelet Count (×10^9/L)</td>
<td>65.8 ±3.46</td>
</tr>
<tr>
<td>Bleeding tendency</td>
<td>Epistaxis</td>
<td>Creatinine (mg/dl)</td>
<td>0.93±0.023</td>
</tr>
<tr>
<td></td>
<td>Per gums</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Per rectum</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Purpura</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vaginal bleeding</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepato-splenomegally</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphadenopathy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

WBC : White blood cell.
ANC: Absolute neutrophil Count.
AST: Aspartate transaminase.
ALT: Alanine transaminase
### Table 2: Serum Zn, Cu, Pb and Cd Levels of the Leukemia patients and healthy control

<table>
<thead>
<tr>
<th></th>
<th>Zinc content (mean±SD) μg/ml</th>
<th>Copper level (mean±SD) μg/ml</th>
<th>Lead level (mean±SD) μg/ml</th>
<th>Cadmium level (mean±SD) μg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DPA, SV</td>
<td>ICP-OES</td>
<td>DPA, SV</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Leukemia patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max</td>
<td>1.8801 ± 0.122</td>
<td>1.9902 ± 0.161</td>
<td>1.8372 ± 0.212</td>
<td>1.9521 ± 0.192</td>
</tr>
<tr>
<td>Min</td>
<td>0.0998 ± 0.012</td>
<td>0.1205 ± 0.011</td>
<td>0.1894 ± 0.013</td>
<td>0.2143 ± 0.014</td>
</tr>
<tr>
<td>Mean</td>
<td>0.5606 ± 0.031</td>
<td>0.5505 ± 0.041</td>
<td>0.8180 ± 0.011</td>
<td>0.8029 ± 0.021</td>
</tr>
<tr>
<td>Healthy control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min</td>
<td>0.1221 ± 0.022</td>
<td>0.1522 ± 0.075</td>
<td>0.1755 ± 0.011</td>
<td>0.1674 ± 0.013</td>
</tr>
<tr>
<td>Mean</td>
<td>0.9753 ± 0.075</td>
<td>0.9561 ± 0.062</td>
<td>0.4070 ± 0.018</td>
<td>0.425 ± 0.014</td>
</tr>
</tbody>
</table>
Table 3. Serum Zn, Cd, Pb and Cu Levels of the Participants using DPA<sub>SV</sub>

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients (n=20)</th>
<th>Controls (n=15)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zn (μg/ml)</td>
<td>0.561±0.497</td>
<td>0.969±0.599</td>
<td>P=0.035</td>
</tr>
<tr>
<td>Cd (μg/ml)</td>
<td>0.0102±0.0173</td>
<td>0.0297±0.270</td>
<td>P=0.014</td>
</tr>
<tr>
<td>Pb (μg/ml)</td>
<td>0.2336±0.216</td>
<td>0.2988±0.213</td>
<td>P=0.381</td>
</tr>
<tr>
<td>Cu (μg/ml)</td>
<td>0.8180±0.468</td>
<td>0.4067±0.200</td>
<td>P=0.003</td>
</tr>
</tbody>
</table>

Zn, Zinc; Cd, Cadmium; Pb, Lead; Cu, Copper

All results are expressed as mean and standard deviation (mean ± SD); P value < 0.05 was considered statistically significant

Table 4. Comparative mean of Serum Zn, Cd, Pb and Cu Levels of the controls using ICP & DPA<sub>SV</sub>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control (n=15)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ICP</td>
<td>DPA&lt;sub&gt;SV&lt;/sub&gt;</td>
</tr>
<tr>
<td>Zn (μg/ml)</td>
<td>1.080±0.599</td>
<td>0.969±0.599</td>
</tr>
<tr>
<td>Cd (μg/ml)</td>
<td>0.1297±0.027</td>
<td>0.0297±0.027</td>
</tr>
<tr>
<td>Pb (μg/ml)</td>
<td>0.399±0.213</td>
<td>0.299±0.213</td>
</tr>
<tr>
<td>Cu (μg/ml)</td>
<td>0.519±0.199</td>
<td>0.4067±0.199</td>
</tr>
</tbody>
</table>

All results are expressed as mean and standard deviation (mean ± SD); P value < 0.05 was considered statistically significant

* Very highly significant

Fig. 1: DPAS Voltammograms of Zn(II) in blood serum of patients with acute leukemia in presence of 0.01M HNO<sub>3</sub> acid solution, pH ~2 at deposition potential -1.2 V and different deposition times. (a) zero; (b) 10; (c) 20; (d) 30; (e) 40; (f) 50; (g) 60 sec.
Determination Of Zinc, Copper, Cadmium And Lead In Serum Of Patients

Fig. 2: DPAS Voltammograms of Zn(II) in blood serum sample of leukemia patient spiked with different concentrations of Zn(II) ions in 0.01M HNO₃ acid solution, pH ~ 2 at deposition potential -1.2V and deposition time 10 sec, (a) sample, S; (b) S+0.5×10⁻⁷; (c) S+1×10⁻⁷; (d) S+1.5×10⁻⁷; (e) S+2×10⁻⁷; (f) S+2.5×10⁻⁷; (g) S+3×10⁻⁷; (h) S+3.5×10⁻⁷; (i) S+4×10⁻⁷ M Zn(II).

Fig. 3: DPAS Voltammograms of Cu(II) in blood serum sample of leukemia patient spiked with different concentrations of Cu(II) ions in 0.01M HNO₃ acid solution, pH ~ 2 at deposition potential -0.25V and deposition time 30 sec, (a) sample, S; (b) S+1.0×10⁻⁷; (c) S+2.0×10⁻⁷; (d) S+3.0×10⁻⁷; (e) S+4.0×10⁻⁷; (f) S+5.0×10⁻⁷; (g) S+6.0×10⁻⁷; (h) S+7.0×10⁻⁷ M Cu(II).
Fig. 4: DPAS Voltammograms of Pb(II) in blood serum sample of leukemia patient spiked with different concentrations of Pb(II) ions in 0.01M HNO₃ acid solution, pH ~ 2 at deposition potential -0.6V and deposition time 30 sec, (a) sample, S; (b) S+1.0×10⁻⁸; (c) S+2.0×10⁻⁸; (d) S+3.0×10⁻⁸; (e) S+4.0×10⁻⁸; (f) S+5.0×10⁻⁸; (g) S+6.0×10⁻⁸; (h) S+7.0×10⁻⁸ M Pb(II).

Fig. 5: DPAS Voltammograms of Cd(II) in blood serum sample of leukemia patient spiked with different concentrations of Cd(II) ions in 0.01M HNO₃ acid solution, pH ~ 2 at deposition potential -0.75V and deposition time 90 sec, (a) sample, S; (b) S+2.0×10⁻⁹; (c) S+4.0×10⁻⁹; (d) S+6.0×10⁻⁹; (e) S+8.0×10⁻⁹; (f) S+10.0×10⁻⁹; (g) S+12.0×10⁻⁹; (h) S+14.0×10⁻⁹ M Cd(II).
Fig. 6. Comparative mean of Cu, Zn, Pb and Cd levels in the serum of leukemic patients and controls using DPAdSV.